Vivet Therapeutics, a clinical-stage biotech company dedicated to developing gene therapy
Vivet Therapeutics BD Director, Thomas Daniel-Robin
Vivet Therapeutics CEO, Jean-Philippe Combal, will be participating to a panel during 2021 World Orphan Drug Congress Europe in Barcelona (Nov 15-18).
Vivet Therapeutics is very pleased and proud to have won the Prix Galien MedStartup Award for “Best Collaboration For the Developing Or Underserved Populations Worldwide”.
VIVET THERAPEUTICS ANNOUNCES 2 ORAL PRESENTATIONS AND 4 ABSTRACTS AT 2021 ESGCT ANNUAL MEETING
Vivet CDO, Anne Douar, will be presenting
Wilson Disease is a rare, progressive genetic disorder that causes excess copper to be stored in the body.
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
Learn how gene therapy aims to target the cause of Wilson disease by delivering a working ATP7B gene into cells. ClinicalTrials are now open for this investigational therapy.
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!